Relatively new posting here but been through the ups and
Relatively new posting here but been through the ups and downs with CYDY this year. Enough to know this:
Posted On: 12/10/2020 3:09:38 AM
Posted By: SizzlChest
Re: gestalt2 #67489
Shorts need greedy people and panic buying to jump in and run the price up... They can do this by creating momentum each day buying enough shares when the price is down to get the ball rolling. (you remember in july when it was jumping 15% a day for a week or so? I believe the first day or two was mainly coordinated purchases by shorters taking 'long positions', and then incrementally selling off those positions as the feeding frenzy they created played itself out) They could have also sold off the remaining shares they owned the day of the short attack knowing they were going to short the stock once they cleared their long positions... They created the upward momentum, fed the boards with articles and wild price speculations and then collected money selling their stocks they purchased and then made even more shorting after those stocks were sold and putting out disinformation. The articles they publish arent just hit pieces, they can be fluff pieces too.
One other thing I have noticed in the last week is when I log on (once a day usually after midnight) There are three pages of new post for me to read as opposed to the half page/ one page for the past month or so... I remember this was happening before the selloff in July too. Not everyone is as they seem. Buyer beware and never gamble more than you can afford to lose.
GLTA longs
And I also mentioned this too: Looks like it is happening and possibly being expedited by the new vaccines...
Posted On: 12/14/2020 11:31:39 PM
Posted By: SizzlChest
Re: Goosebumps #68143
Viruses mutate... They do not want to kill their host, because then they cannot propagate if the host dies.
And finally todays post before the Merck news hit:
Posted On: 12/23/2020 3:16:10 AM
Posted By: SizzlChest
Re: smurph #69335
There ya go. I did forget that the FDA gave us remdisivir as a therapeutic... A drug that is useless but managed to make some quick$$$ for Gilead... I guess that was their consolation prize for letting Pfizer get the vaccine.
The FDA is stalling LL to buy time for 1 Vaccines and 2 BP to come up with a competing drug with LL and give it fast approval.
I think I know quite a bit about investing in this stock, not looking to sell. Unfortunately my buy order I set at $4.40 did not hit today. I will reset it for $4.22 tomorrow
but this is what I really wanted to happen:
Posted On: 12/22/2020 2:26:09 AM
Posted By: SizzlChest
Re: CDiddy #69139
I hope the shorts do jump and I hope the market views this as negative and the price drops below 4$... I just put some more coin in the coffers, so I've got my buy orders ready...
Yeah, I think I've got a pretty good idea about this stock.
Now the people jumping on asking everyone if they think the price is going to go down because the CFO is selling? They need to be ignored
Merry Christmas everyone... Hopefully the mutated virus that is going to hit the U.S. next week isn't nearly as deadly... We will still need LL more than ever though
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Top 5 Most Recently Viewed Articles
Shell plc made some serious moves back in September 2024 that had traders scratching their heads and looking for the fine print. They let loose a slew of notifications about share transactions by its Persons Discharging Managerial Responsibilities (PDMRs), making waves in the market. This isn’t just corporate fluff; it’s a playbook for transparency and compliance that...
Continue Reading
Unpacking the Explosive Allegations Against zSpace You think you're safe diving into augmented reality stocks, and then a bombshell lands. zSpace, Inc. (NASDAQ:ZSPC), a supposed leader in AR and VR educational tech, finds itself in the swirling midst of a class action lawsuit. Investors are rattled, and they're not just buzzing because their portfolios took a hit. There's...
Continue Reading
WisdomTree Introduces Earn-Until-You-Spend Feature WisdomTree, Inc. (NYSE: WT), a leader in financial innovation, has recently announced a significant enhancement to its user experience with the introduction of a new feature allowing customers to utilize their accrued interest from the WisdomTree Government Money Market Digital Fund (WTGXX) as a funding source for the...
Continue Reading
AVITA Medical to Report Financial Results AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a prominent company in therapeutic acute wound care, has made headlines with its upcoming financial disclosure. The firm is set to unveil its third-quarter financial results for 2025 after the U.S. markets close on the scheduled date. This announcement is anticipated by investors who...
Continue Reading
Hyperscale Data's Commendable Dividend Achievement LAS VEGAS — Hyperscale Data, Inc. (NYSE: GPUS) proudly announced it has consistently paid cash dividends for twenty-eight consecutive months on its Series D Preferred Stock. This dividend, amounting to 13.00% annually, equates to approximately $0.2708 for each share, paid monthly. This remarkable track record...
Continue Reading